Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages 623-632

  Chung, Jina ^a   Duffin, Kristina Callis ^c   Takeshita, Junko ^a,b   Shin, Daniel B ^a,b   Krueger, Gerald G ^c   Robertson, Andrew D ^d   Troxel, Andrea B ^b   Van Voorhees, Abby S ^a   Edson Heredia, Emily ^e   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d National Psoriasis Foundation   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Epidemiology; Health related quality of life; Palmoplantar psoriasis; Patient reported outcomes; Plaque psoriasis; Psoriasis

Indexed keywords

ETRETIN;

ADULT; ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS QUESTIONNAIRE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SYSTEMIC THERAPY; ADAPTIVE BEHAVIOR; AGE; CLASSIFICATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; FOOT; HAND; HEALTH-RELATED QUALITY OF LIFE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOMES; PSORIASIS; PSYCHOLOGICAL ASPECT; RISK; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SICKNESS IMPACT PROFILE; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

EPIDEMIOLOGY; HEALTH-RELATED QUALITY OF LIFE; PALMOPLANTAR PSORIASIS; PATIENT-REPORTED OUTCOMES; PLAQUE PSORIASIS; PSORIASIS;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGE FACTORS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; FOOT; HAND; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 84910115973     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.04.063     Document Type: Article

References (57)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60: 218-24.
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
3. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013;149:1173-9.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
5. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-8.
6. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31: 1000-6.
7. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013;149:84-91.
8. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 2013;347:f5961.
9. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
10. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20.
11. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
12. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012;7:28.
13. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
14. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94.
15. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137: 755-60.
16. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-44.
17. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-relatedquality of life. J AmAcadDermatol 2002;47:512-8.
18. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
19. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989;20:53-63.
20. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
21. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003;49:271-5.
22. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009;60:1024-31.
23. Elahmed HH. Rapid improvement of palmoplantar psoriasis after cessation of smoking. Sultan Qaboos Univ Med J 2013; 13:188-9.
24. Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 2009;23:814-9.
25. Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg 2007;11:202-5.
26. Jacobi A, Schuler G, Hertl M. Differential clinical response to alefacept in combination with methotrexate in two patients with refractory palmar psoriasis. Br J Dermatol 2007;156: 178-80.
27. Schroder K, Zaun H, Holzmann H, Altmeyer P, el-Gammal S. Pustulosis palmo-plantaris: clinical and histological changes during etretin (acitretin) therapy. Acta Derm Venereol Suppl (Stockh) 1989;146:111-6.
28. Al-Mutairi N, Joshi A, Nour-Eldin O. Punctate palmoplantar keratoderma (Buschke-Fischer-Brauer disease) with psoriasis: a rare association showing excellent response to acitretin. J Drugs Dermatol 2005;4:627-34.
29. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001;40:541-2.
30. Rivard J, Janiga J, Lim HW. Tacrolimus ointment 0. 1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol 2006;5:505-10.
31. Cohen DJ, Scherschun L. Case reports: practical experience with efalizumab in hand and foot psoriasis. J Drugs Dermatol 2007;6:1224-30.
32. Kircik L. Treatment of hand and foot psoriasis with emphasis on efalizumab. Skin Therapy Lett 2007;12:4-7.
33. Ravi Kumar BC, Kaur I, Kumar B. Topical methotrexate therapy in palmoplantar psoriasis. Indian J Dermatol Venereol Leprol 1999;65:270-2.
34. Coleman WR, Lowe NJ, David M, Halder RM. Palmoplantar psoriasis: experience with 8-methoxypsoralen soaks plus ultraviolet A with the use of a high-output metal halide device. J Am Acad Dermatol 1989;20:1078-82.
35. Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol 2010;3:37-40.
36. Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). Eur J Dermatol 2012;22: 231-7.
37. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol 2012;148:487-94.
38. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75.
39. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)ea simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
40. EuroQol Group. EuroQolea new facility for the measurement of health-related quality of life. Health Policy 1990;16: 199-208.
41. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20.
42. van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend 2006;82:111-8.
43. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3:17.
44. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997;16:2529-42.
45. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988;119:755-9.
46. Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162:952-63.
47. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
48. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 2002;82:192-5.
49. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998;138:390-8.
50. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and metaanalysis. Br J Dermatol 2013;11:12670.
51. Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 2013;168:1243-51.
52. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141: 1527-34.
53. Hellgren L, Mobacken H. Pustulosis palmaris et plantaris: prevalence, clinical observations and prognosis. Acta Derm Venereol 1971;51:284-8.
54. Enfors W, Molin L. Pustulosis palmaris et plantaris: a follow-up study of a ten-year material. Acta Derm Venereol 1971;51:289-94.
55. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006;4:71.
56. Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol 2008;22:392-3.
57. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-32.